When I broke down Johnson & Johnson’s (NYSE: JNJ) first-quarter earnings on April 15, my central argument wasn’t really about Stelara. It was about what Stelara represented – a company approaching one of the largest patent cliffs in its history with a margin for error that was beginning to visibly narrow, and a growth story increasingly dependent on whether a handful of successor products could absorb the erosion fast enough to keep the headline numbers intact.
Three months later, the conversation has changed. Not because the patent cliff disappeared, but because this 2nd quarter provided genuine evidence that Johnson & Johnson may be building a business where no single expiry can dictate the entire investment thesis anymore.
Let’s Talk About The Mechanism Behind The Headline Numbers
Johnson & Johnson reported adjusted EPS of $2.90 on $25.3 billion in revenue, beating Wall Street’s expectations comfortably and raising full-year guidance to $100.8–$101.4 billion in revenue alongside adjusted EPS guidance of $11.50–$11.65. Adjusted operational sales grew 5.8%, and this marks the second consecutive quarter where management had enough confidence in the forward trajectory to lift the outlook rather than simply defend it.
What’s even more impressive is the context they were produced inside. Stelara is still creating roughly a 460-basis-point drag on company-wide sales, a headwind large enough to derail most pharmaceutical earnings stories, and Johnson & Johnson (NYSE: JNJ) still delivered 6.6% revenue growth and raised guidance anyway. That combination is not something most drug companies achieve while absorbing a biosimilar erosion of this magnitude, and the fact that it happened doesn’t mean the patent cliff problem has been solved. It means the rest of the business has grown large and diversified enough to absorb a hit that would have been far more damaging even two years ago.
How The Company Reduced Its Dependence On Stelara
The traditional pharmaceutical model has always rested on a version of the same cycle: one breakthrough drug drives years of growth, one patent expiry threatens years of growth, and the entire investment case pivots around whether the pipeline can produce a successor in time. That cycle hasn’t disappeared from Johnson & Johnson’s story, but this 2nd quarter earnings suggest the company is systematically reducing its influence over the outcome, and the distinction between replacing a blockbuster and reducing dependence on one is more important than it might appear.
Inside Innovative Medicine, Stelara created roughly a 760-basis-point drag on segment sales, yet the division still generated $16.4 billion in revenue and grew 7.8% on a reported basis. Darzalex continued expanding its leadership in multiple myeloma, Carvykti maintained its commercial rollout, Tremfya kept gaining share across immunology, and Rybrevant and Lazcluze continued building out the oncology franchise. MedTech added another $8.9 billion, growing 4.5%, with Shockwave, Electrophysiology, and Vision all contributing to a segment that operates largely independently of the pharmaceutical patent cycle entirely.
Unlike most pharmaceutical companies, the growth wasn’t concentrated in one product being positioned as the next Stelara. It was distributed across multiple businesses in multiple categories, each carrying a different expiry timeline and a different competitive dynamic. That distribution is precisely the shift worth tracking, because a company where ten products each contribute meaningfully is a structurally different risk profile from a company where two products carry the entire story, and Johnson & Johnson is gradually moving toward the former.
Institutional Conviction?
The immediate earnings reaction wasn’t particularly encouraging, with shares pulling back from briefly touching $258 to finish the session around $247.37. Taken in isolation, that’s easy to read as disappointment. Placed in the context of the broader chart, it looks considerably more like a post-earnings reset inside an intact uptrend than the beginning of a more serious reassessment.
Shares continue trading comfortably above the 50-day moving average at $237.60 and the 200-day moving average at $222.21, preserving the structural uptrend that has been building since the spring, while the 20-day moving average at $250.16 now becomes the first level investors will watch as the stock attempts to reclaim momentum. Trading volume of roughly 221,800 shares during the session doesn’t suggest broad institutional liquidation. It suggests the kind of modest profit-taking that typically follows a beat-and-raise quarter that had already been partially anticipated by the move heading into it.
For a company navigating one of the most significant patent expirations in the pharmaceutical industry’s recent history, a chart that continues respecting every major moving average and holding a multi-month uptrend is telling you something about how the market is weighing the longer-term thesis against the near-term Stelara noise.
Next Question
Every pharmaceutical company faces patent cliffs. That’s a structural feature of the industry that separates companies capable of compounding through disruption from those that require a single breakthrough to sustain the entire story. And the companies that keep creating shareholder value through those transitions aren’t necessarily the ones that avoid the cliffs. They’re the ones that make sure no single drug carries enough influence to derail the business once exclusivity expires.
That’s the framework I’ll carry into Johnson & Johnson’s next several quarters – whether revenue continues arriving from a broadening collection of products, therapies, and medical technologies that share the load rather than concentrate it. Because if that distribution keeps widening, future patent expirations become events to monitor rather than crises to manage, and that would represent a far more durable shift than any single strong quarter can capture on its own.
